Literature DB >> 26572926

Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations.

Archana M Rajan1, Francis K Buadi2, Vincent Rajkumar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26572926      PMCID： PMC4724346          DOI： 10.1002/ajh.24244

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

Authors:  S Vincent Rajkumar; Paul Richardson; Jesus F San Miguel
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal:  Lancet Oncol       Date:  2010-08-23       Impact factor: 41.316

Review 3.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

4.  Effect of thalidomide on gastrointestinal toxic effects of irinotecan.

Authors:  R Govindarajan; K M Heaton; R Broadwater; A Zeitlin; N P Lang; M Hauer-Jensen
Journal:  Lancet       Date:  2000-08-12       Impact factor: 79.321

5.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Davide Rossi; Maide Cavalli; Alessandra Larocca; Roberto Ria; Massimo Offidani; Francesca Patriarca; Chiara Nozzoli; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Luca Baldini; Fortunato Morabito; Mariella Grasso; Giovanna Leonardi; Manuela Rizzo; Antonietta Pia Falcone; Daniela Gottardi; Vittorio Montefusco; Pellegrino Musto; Maria Teresa Petrucci; Giovannino Ciccone; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 6.  Management of thalidomide toxicity.

Authors:  Irene M Ghobrial; S Vincent Rajkumar
Journal:  J Support Oncol       Date:  2003 Sep-Oct

7.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

Review 8.  Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2014-10       Impact factor: 10.047
  8 in total
  2 in total

Review 1.  Efficacy of Panobinostat for the Treatment of Multiple Myeloma.

Authors:  Evangelos Eleutherakis-Papaiakovou; Nikolaos Kanellias; Efstathios Kastritis; Maria Gavriatopoulou; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  J Oncol       Date:  2020-01-13       Impact factor: 4.375

Review 2.  Multiple myeloma current treatment algorithms.

Authors:  S Vincent Rajkumar; Shaji Kumar
Journal:  Blood Cancer J       Date:  2020-09-28       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.